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See Article, pages 876–884It is now widely accepted that primary biliary cirrhosis (PBC) is a
complex disorder, with both genetic and environmental factors
contributing to its pathogenesis. Over the last two years signiﬁ-
cant light has been shed on the potential genetic factors contrib-
uting to PBC, with several genome-wide associations studies
(GWAS) showing highly consistent results, all pointing to a strong
genetic susceptibility to PBC relating, typically, to genes which
regulate the immune response in general and antigen presenta-
tion and T-cell priming in particular [1,2]. Taken together, these
studies all point to dysregulated immunity playing an important
role in the disease. Less progress has been made, however, in
identifying environmental factors which could be triggering the
disease process in susceptible individuals, although the existence
of such a factor is strongly supported by epidemiological studies
which have identiﬁed disease clusters [3,4]. Although these
observations have been interpreted as supporting a chemical
environmental factor, they could equally well support an infec-
tious factor. This possibility is particularly supported by the most
recent clustering study, carried out in the North-East of England,
which identiﬁed both temporal as well as spatial clustering in
disease patterns [4]; an observation compatible with person-to-
person or vector transmission.
To date, however, no infectious agent has been unequivocally
linked with PBC risk. There are some data to support chronic uri-
nary tract infections (UTI), although causality has always proved
difﬁcult (the issue is whether patients with recurrent urinary
tract infections are predisposed to developing PBC or, conversely,
whether the trophic changes within the urinary tract seen in PBC
patients predispose to UTI). One of the most contentious postu-
lated models for infectious triggering of PBC has been the betaret-
rovirus model postulated by the Mason Group [5–7]. In a series of
publications, this group has identiﬁed serological responses to
retroviruses in PBC patients, described the presence of ‘‘viral’’ par-
ticles in cultured biliary epithelial cells (BEC) from PBC patients,
and identiﬁed the presence of viral nucleic acid in draining lymph
nodes from PBC patients’ livers (and, at much lower frequency, in
liver and serum). The group has postulated that one of theJournal of Hepatology 20
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regulation of pyruvate dehydrogenase complex (PDC, the auto-
antigen in PBC), or a cross-reactive protein, by BEC [8], is a
consequence of the actions of the retrovirus, co-culture of BEC
from normal subjects with tissue extract from PBC-patient liver
draining lymph-node resulting in, seemingly, transfer of the effect
into the naive cell cultures. The model proposed by the Mason
group is that the actions of the betaretrovirus on antigen expres-
sion generates neo-antigens which induce immune responses
cross-reactive with self-PDC, breaking tolerance and triggering
the autoimmune phase of the disease (an ‘‘altered-self’’ model
for autoimmunity). The potential importance of the model clearly
lies in the opportunity, if the model is correct, to modify retrovi-
rus as a risk factor through the use of anti-retroviral drugs [9].
Although seductive, the retroviral aetiology model for PBC has
proved highly controversial, with other groups challenging the
primary ﬁndings, and no group successfully reproducing the
key observations [10–12] (although, it should be noted, no group
has attempted to replicate the study of liver draining lymph
nodes from PBC patients; the tissue with the highest level of viral
expression in the original report [6,12]). Furthermore, alternative
explanations can be put forward for many of the key observations
(for example cell surface expression of PDC can occur as a conse-
quence of apoptosis meaning that any factor which could be
transferred from one cell culture to another, and which induces
cells to undergo apoptosis, would seemingly ‘‘transmit’’ the cell
surface PDC expression phenotype [13]). The controversy
surrounding the model, and the associated debate around the
equivalence of methods used in the different studies, can lead
the non-expert unclear as to what the ﬁndings mean (if anything)
for PBC patients.
The counter-view regarding PBC pathogenesis is that it is a
classical autoimmune disease, a suggestion strongly supported
by the high titre auto-antibodies, presence of auto-reactive T-
cells, association with other auto-immune diseases, and, latterly,
the strong immuno-genetic associations described in PBC [14].
One of the recent strands of evidence supporting a purely auto-
immune model for PBC pathogenesis of PBC is the work by the
Gershwin group and others identifying spontaneous murine
models which develop serological and histological features which
are suggestive of PBC [15–17]. These spontaneous models, in
animals with speciﬁc immuno-regulatory abnormalities, would11 vol. 55 j 750–752
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appear to support the concept emerging from the human GWAS
studies that it is immune dysregulation which predisposes to
PBC; the classical autoimmune model. One of the key models of
this type is the NOD.c3.c4 mouse, a congenic non-diabetic deriv-
ative of the classical NOD mouse which develops intra-hepatic
bile duct damage redolent of PBC in the context of anti-PDC
auto-antibodies [15,18] (as well as some other less typical fea-
tures). To date, there are no data to suggest that environmental
factors might be necessary to promote the development of bile
duct abnormality in these animals.
In the current edition of the Journal of Hepatology the Mason
group have attempted to draw together these disparate strands
of research [19]. In the study, they explored the biology of the
NOD.c3.c4 mouse and other murine models of PBC and, in partic-
ular, looked for the presence of mouse mammary tumour virus
(MMTV), a murine retrovirus which has almost complete
sequence homology with the postulated human PBC betaretrovi-
rus. NOD.c3.c4 mice expressed MMTV surface and capsid proteins
on the biliary epithelium, together with a protein which was
cross reactive with PBC E2. The other animal models also
expressed MMTV proteins and aberrant PBC-E2-like protein in
the spleen. All animals expressed MMTV gag and env in the liver.
A signiﬁcant correlation was seen between anti-MMTV antibody
production and anti-PDC autoantibody production in the sera of
the NODc3.c4 mice.
MMTV transmission in mice is typically in the neonatal period
through breast milk. Although causal associations are not demon-
strated in this study, the model the authors propose is that such
neonatal exposure to the MMTV leads to chronic infection which
alters PDC (or PDC homologue) expression within tissues, predis-
posing to subsequent breakdown of immune tolerance resulting
in the development of autoimmunity. In this model, the
immuno-genetic abnormalities in the mice either predispose to
chronicity of infection in the ﬁrst place, or to the secondary
breakdown in tolerance to PDC promoted by altered self-antigen
processing or the expression of a viral homologue (or of course
both processes).
The ﬁndings of the study have the potential to both advance
the ﬁeld and to add further confusion to an already confused pic-
ture. At one end of the range of possibilities (and the end that the
authors would no doubt support) the ﬁndings suggest that the
NOD.c3.c4 model (and to a lesser extent the other two models)
fully models the changes which are present in PBC, with an
immuno-genetic susceptibility and retroviral exposure combin-
ing to promote tolerance breakdown. In this scenario, the murine
models would present a perfect context in which to do pre-clin-
ical testing of anti-retroviral interventions of potential beneﬁt to
PBC patients. At the other end of the range of possibilities, the
observations of un-anticipated pathogen differences in different
sub-strains of animals potentially confound the validity of these
models for PBC as an autoimmune disease.
Critical to understanding the value or otherwise of the ﬁnd-
ings of Zhang et al. will be the extent to which they can be repro-
duced by other groups; a scenario identical to the situation with
the human retroviral model. It is critical now that both the
human and the murine retroviral stories are explored in a co-
ordinated way by independent laboratories using standardised
approaches and reagents. Only then, will we understand whether
we now have the perfect murine model for PBC (a similar
pathogenic trigger on a similar immunogenetic background) or
whether we simply have artefact. That this controversy is ﬁnallyJournal of Hepatology 201resolved is important for researchers in the ﬁeld. It is, however,
particularly important for patients with PBC. The issue of a viral
aetiology for PBC has given rise to hope for novel therapies, and
the existence of clinical trials to address the effect of anti-retro-
viral therapies has supported this hope. Arguments about the
veracity of models such as the retroviral model in PBC are normal
for scientists, but confusing for patients who now don’t know
whether this model does or does not offer them the potential
for curative therapy. It is beholden on those who work in the ﬁeld
to work together to address the areas of scientiﬁc uncertainty and
to give patients an answer.Conﬂict of interest
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